According to FutureWise analysis, the microfluidic immunoassay market in 2026 is US$1.86 billion, and is expected to reach US$4.71 billion by 2036 at a CAGR of 9.74%.
The microfluidic immunoassay market is experiencing significant growth, largely fueled by the increasing demand for point-of-care diagnostics and the rising incidence of chronic diseases that necessitate rapid testing solutions. Advances in technology, particularly in lab-on-a-chip devices and miniaturization techniques, are contributing to the development of more accurate and cost-effective diagnostic platforms. Currently, North America holds the largest share of the market, followed by Europe and the Asia-Pacific region, where emerging markets are showing faster adoption rates. Key applications within this market include testing for infectious diseases, detection of cancer biomarkers, and cardiovascular diagnostics. Moreover, the ongoing shift toward personalized medicine and the growing trend of home-based testing, especially in the aftermath of the pandemic, are further propelling the expansion of the market.
The microfluidic technology has recently garnered substantial interest. This is primarily owing to the reduced need of separate instruments with the integration of entire lab process on a single chip. The microfluidic system has showcased promising results in the immunosensor division. These sensors provide substantial benefits over traditional methods like high surface to volume ratio to transport efficient mass in immunoreactions. Such advancements in immunosensors and the increasing prevalence of diseases, the market is likely to showcase substantial growth during the forecast period.
Paper based microfluidics is the new microfluidic immunoassay market trend and this is mainly owing to many benefits of paper material like low cost of substrate material and which is compatible with a variety of medical applications. Furthermore, an extensive research has been conducted over paper-based microfluidics. For instance, Diagnostics for All Inc. develops paper-based LOC that costs low aiming at providing low-cost diagnostics to developing and underdeveloped nations. As the research for paper-based microfluidics has been financed heavily, it is likely to create an efficient alternative for traditional diagnostic devices over the coming years.